Balyasny Asset Management LLC Theravance Biopharma, Inc. Transaction History

Balyasny Asset Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$8.29 - $9.92 $23,394 - $27,994	2,822 Added 9.02%	34,107 $289,000
Q1 2024 May 13, 2024	BUY	$8.22 - $11.59 $257,162 - $362,593	31,285 New	31,285 $280,000
Q3 2023 Nov 14, 2023	BUY	$8.38 - $10.44 $114,797 - $143,017	13,699 New	13,699 $118,000
Q2 2018 Aug 14, 2018	SELL	$22.06 - $25.52 $1.44 Million - $1.66 Million	-65,149 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$23.37 - $29.71 $550,199 - $699,462	-23,543 Reduced 26.54%	65,149 $1.58 Million
Q4 2017 Feb 14, 2018	SELL	$25.82 - $35.66 $2.37 Million - $3.28 Million	-91,908 Reduced 50.89%	88,692 $2.47 Million
Q3 2017 Nov 14, 2017	BUY	$23.88 - $34.96 $4.31 Million - $6.31 Million	180,600	180,600 $6.18 Million

128

47M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $609M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.